6-weekly bevacizumab versus 4-weekly ranibizumab for neovascular age-related macular degeneration: a 2-year outcome
AIM: To compare visual acuity and central macular thickness (CMT) changes in neovascular age related macular degeneration patients treated with either 6 weekly bevacizumab regimen or 4 weekly ranibizumab on an as required basis. METHODS: Patients made an informed choice between bevacizumab 1.25 mg...
Main Authors: | , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Press of International Journal of Ophthalmology (IJO PRESS)
2016-04-01
|
Series: | International Journal of Ophthalmology |
Subjects: | |
Online Access: | http://www.ijo.cn/en_publish/2016/4/20160412.pdf |
id |
doaj-8aebc59a2e4b4e80ab91065777226325 |
---|---|
record_format |
Article |
spelling |
doaj-8aebc59a2e4b4e80ab910657772263252020-11-24T21:08:38ZengPress of International Journal of Ophthalmology (IJO PRESS)International Journal of Ophthalmology2222-39592227-48982016-04-019455155510.18240/ijo.2016.04.126-weekly bevacizumab versus 4-weekly ranibizumab for neovascular age-related macular degeneration: a 2-year outcomePatrick J Chiam0Vivian W Ho1Nicholas M Hickley2Venkat Kotamarthi3St.Paul’s Eye Unit, Royal Liverpool University Hospital, Liverpool L7 8XP, UK; Eye Care Centre, Leighton Hospital, Crewe CW1 4QJ, UK; Eye Department, Leicester Royal Infirmary, Leicester LE1 5WW, UKSt.Paul’s Eye Unit, Royal Liverpool University Hospital, Liverpool L7 8XP, UK; Eye Care Centre, Leighton Hospital, Crewe CW1 4QJ, UKSt.Paul’s Eye Unit, Royal Liverpool University Hospital, Liverpool L7 8XP, UK; Eye Care Centre, Leighton Hospital, Crewe CW1 4QJ, UKEye Care Centre, Leighton Hospital, Crewe CW1 4QJ, UKAIM: To compare visual acuity and central macular thickness (CMT) changes in neovascular age related macular degeneration patients treated with either 6 weekly bevacizumab regimen or 4 weekly ranibizumab on an as required basis. METHODS: Patients made an informed choice between bevacizumab 1.25 mg or ranibizumab 0.5 mg. The selected treatment was administered in the first 3 visits. Bevacizumab patients were followed-up 6 weekly and ranibizumab 4 weekly. Retreatment criteria was based on the reduction of >5 letters in the best-corrected visual acuity (BCVA), the presence of retinal fluid on optical coherence tomography (OCT) or new retinal haemorrhage. RESULTS: Visual acuity at 2y bevacizumab patients gained 7.0 letters and ranibizumab 9.2 (P=0.31, 95% CI -6.4 to 2.0). At 2y 86% of bevacizumab and 94% ranibizumab patients had not lost 15 letters or more (P=0.13). Mean CMT decreased at 2y bevacizumab by 146 µm, ranibizumab 160 µm (P=0.72). Mean number of injections was at 2y bevacizumzb 11.9, ranibizumab 10.3 (P=0.023). CONCLUSION: Bevacizumab 6 weekly on an as required basis was not demonstrably non-inferior to ranibizumab 4 weekly pro re nata (prn) in terms of BCVA and change in CMT. In the bevacizumab group, one more injection was required in the second year compared to the ranibizumab group.http://www.ijo.cn/en_publish/2016/4/20160412.pdfbevacizumabranibizumabneovascular age-related macular degenerationtreatment on as required basis |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Patrick J Chiam Vivian W Ho Nicholas M Hickley Venkat Kotamarthi |
spellingShingle |
Patrick J Chiam Vivian W Ho Nicholas M Hickley Venkat Kotamarthi 6-weekly bevacizumab versus 4-weekly ranibizumab for neovascular age-related macular degeneration: a 2-year outcome International Journal of Ophthalmology bevacizumab ranibizumab neovascular age-related macular degeneration treatment on as required basis |
author_facet |
Patrick J Chiam Vivian W Ho Nicholas M Hickley Venkat Kotamarthi |
author_sort |
Patrick J Chiam |
title |
6-weekly bevacizumab versus 4-weekly ranibizumab for neovascular age-related macular degeneration: a 2-year outcome |
title_short |
6-weekly bevacizumab versus 4-weekly ranibizumab for neovascular age-related macular degeneration: a 2-year outcome |
title_full |
6-weekly bevacizumab versus 4-weekly ranibizumab for neovascular age-related macular degeneration: a 2-year outcome |
title_fullStr |
6-weekly bevacizumab versus 4-weekly ranibizumab for neovascular age-related macular degeneration: a 2-year outcome |
title_full_unstemmed |
6-weekly bevacizumab versus 4-weekly ranibizumab for neovascular age-related macular degeneration: a 2-year outcome |
title_sort |
6-weekly bevacizumab versus 4-weekly ranibizumab for neovascular age-related macular degeneration: a 2-year outcome |
publisher |
Press of International Journal of Ophthalmology (IJO PRESS) |
series |
International Journal of Ophthalmology |
issn |
2222-3959 2227-4898 |
publishDate |
2016-04-01 |
description |
AIM: To compare visual acuity and central macular thickness (CMT) changes in neovascular age related macular degeneration patients treated with either 6 weekly bevacizumab regimen or 4 weekly ranibizumab on an as required basis.
METHODS: Patients made an informed choice between bevacizumab 1.25 mg or ranibizumab 0.5 mg. The selected treatment was administered in the first 3 visits. Bevacizumab patients were followed-up 6 weekly and ranibizumab 4 weekly. Retreatment criteria was based on the reduction of >5 letters in the best-corrected visual acuity (BCVA), the presence of retinal fluid on optical coherence tomography (OCT) or new retinal haemorrhage.
RESULTS: Visual acuity at 2y bevacizumab patients gained 7.0 letters and ranibizumab 9.2 (P=0.31, 95% CI -6.4 to 2.0). At 2y 86% of bevacizumab and 94% ranibizumab patients had not lost 15 letters or more (P=0.13). Mean CMT decreased at 2y bevacizumab by 146 µm, ranibizumab 160 µm (P=0.72). Mean number of injections was at 2y bevacizumzb 11.9, ranibizumab 10.3 (P=0.023).
CONCLUSION: Bevacizumab 6 weekly on an as required basis was not demonstrably non-inferior to ranibizumab 4 weekly pro re nata (prn) in terms of BCVA and change in CMT. In the bevacizumab group, one more injection was required in the second year compared to the ranibizumab group. |
topic |
bevacizumab ranibizumab neovascular age-related macular degeneration treatment on as required basis |
url |
http://www.ijo.cn/en_publish/2016/4/20160412.pdf |
work_keys_str_mv |
AT patrickjchiam 6weeklybevacizumabversus4weeklyranibizumabforneovascularagerelatedmaculardegenerationa2yearoutcome AT vivianwho 6weeklybevacizumabversus4weeklyranibizumabforneovascularagerelatedmaculardegenerationa2yearoutcome AT nicholasmhickley 6weeklybevacizumabversus4weeklyranibizumabforneovascularagerelatedmaculardegenerationa2yearoutcome AT venkatkotamarthi 6weeklybevacizumabversus4weeklyranibizumabforneovascularagerelatedmaculardegenerationa2yearoutcome |
_version_ |
1716760053715828736 |